Skip to menu Skip to content Skip to footer

2006

Journal Article

Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients

Dansirikul, C., Staatz, C. E., Duffull, S. B., Taylor, P. J., Lynch, S. V. and Tett, S. E. (2006). Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients. Journal of Clinical Pharmacy And Therapeutics, 31 (1), 17-25. doi: 10.1111/j.1365-2710.2006.00697.x

Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients

2006

Conference Publication

National quality improvement initiatives - CAPTION and beyond

Wai, A., Horn, F., Mackson, J. M., Maxwell, D. J., Kaye, K. I., McIntosh, K. A., Robertson, M. B., Stanton, L. A., Peterson, G. M., Marwood, A. C., Dollman, W. B., Pulver, L. K., Tett, S. E., Coombes, J., Petrie, A. and Weekes, L. (2006). National quality improvement initiatives - CAPTION and beyond. 4th Australasian Conference on Safety and Quality in Health Care, Melbourne, Australia, 21st - 23rd August, 2006.

National quality improvement initiatives - CAPTION and beyond

2006

Conference Publication

How did rofecoxib withdrawal influence overall non-steroidal anti-inflammatory drug (NSAIDs) and paracetamol prescribing in Australia?

Barozzi, N. and Tett, S. E. (2006). How did rofecoxib withdrawal influence overall non-steroidal anti-inflammatory drug (NSAIDs) and paracetamol prescribing in Australia?. Quality Use of Medicines: Balancing Beliefs, Benefits and Harms, Canberra / National Convention Centre, 7-9 June 2006. Canberra: National Prescribing Service Limited.

How did rofecoxib withdrawal influence overall non-steroidal anti-inflammatory drug (NSAIDs) and paracetamol prescribing in Australia?

2006

Journal Article

A Bayesian approach for population pharmacokinetic modelling of sirolimus

Dansirikul, Chantaratsamon, Morris, Raymond G., Tett, Susan E. and Duffull, Stephen B. (2006). A Bayesian approach for population pharmacokinetic modelling of sirolimus. British Journal of Clinical Pharmacology, 62 (4), 420-434. doi: 10.1111/j.1365-2125.2005.02533.x

A Bayesian approach for population pharmacokinetic modelling of sirolimus

2006

Conference Publication

Geographical differences in antidepressant and benzodiazepine prescribing in rural and urban Queensland

Coulson, F. R. and Tett, S. E. (2006). Geographical differences in antidepressant and benzodiazepine prescribing in rural and urban Queensland. Quality use of medicines: Balancing beliefs, benefits and harms, National Convention Centre, Canberrra, 7-9 June 2006. Brisbane: National Prescribing Service.

Geographical differences in antidepressant and benzodiazepine prescribing in rural and urban Queensland

2006

Conference Publication

Tinkering with the immune system - When, why and how for optimal therapeutics

Tett, S. E. (2006). Tinkering with the immune system - When, why and how for optimal therapeutics. Canadian Therapeutics Congress, Toronto, Canada, May 2006. Canada: Canadian Association of Population therapeutics; Canadian Society for Clinical Pharmacology.

Tinkering with the immune system - When, why and how for optimal therapeutics

2005

Journal Article

Consumer involvement in quality use of medicines (QUM) projects - lessons from Australia

Kirkpatrick, Carl M. J., Roughead, Elizabeth E., Monteith, Gregory R. and Tett, Susan E. (2005). Consumer involvement in quality use of medicines (QUM) projects - lessons from Australia. BMC Health Services Research, 5 (1) 75, 75.1-75.7. doi: 10.1186/1472-6963-5-75

Consumer involvement in quality use of medicines (QUM) projects - lessons from Australia

2005

Journal Article

Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation

Staatz, Christine E., Duffull, Stephen B., Kiberd, Bryce, Fraser, Albert D. and Tett, Susan E. (2005). Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. European Journal of Clinical Pharmacology, 61 (7), 507-516. doi: 10.1007/s00228-005-0927-4

Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation

2005

Journal Article

Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia

Cooke, C., Nissen, L. M., Sketris, I. S. and Tett, S. E. (2005). Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia. Clinical Therapeutics, 27 (4), 497-508. doi: 10.1016/j.clinthera.2005.04.009

Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia

2005

Conference Publication

How much, how often, how long?

Tett, S. E. (2005). How much, how often, how long?. Joint Meeting of ASCEPT and APSA, Melbourne, 4-7 Dec. 2005. Australia: Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists.

How much, how often, how long?

2005

Conference Publication

Drug utilisation review across jurisdictions: A reality or still a distant dream?

Pulver, L. and Tett, S.E. (2005). Drug utilisation review across jurisdictions: A reality or still a distant dream?. The Society of Hospital Pharmacists of Australia 27th Federal Conference, Brisbane, 10-13 Nov. 2005. Brisbane: Event Planners Australia.

Drug utilisation review across jurisdictions: A reality or still a distant dream?

2005

Journal Article

Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients

Dansirikul, C., Duffull, S. B., Morris, R. G. and Tett, S. E. (2005). Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients. British Journal of Clinical Pharmacology, 60 (5), 560-565. doi: 10.1111/j.1365-2125.2005.02473.x

Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients

2005

Journal Article

Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

Chan, V., Charles, B. G. and Tett, S. E. (2005). Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. British Journal of Clinical Pharmacology, 60 (3), 257-264. doi: 10.1111/j.1365-2125.2005.02415.x

Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

2005

Conference Publication

Directions for pharmacy as we move forward

Tett, S. E. (2005). Directions for pharmacy as we move forward. The Society of Hospital Pharmacists of Australia 27th Federal Conference, Brisbane, 10-13 Nov. 2005. Brisbane: Event Planners Australia.

Directions for pharmacy as we move forward

2005

Journal Article

Empiric management of community-acquired pneumonia in Australian emergency departments

Maxwell, D. J., McIntosh, K. A., Pulver, L. K., Easton, K. L., CAPTION Study Grp and Tett, S. E. (2005). Empiric management of community-acquired pneumonia in Australian emergency departments. Medical Journal of Australia, 183 (10), 520-524. doi: 10.5694/j.1326-5377.2005.tb07153.x

Empiric management of community-acquired pneumonia in Australian emergency departments

2005

Other Outputs

Rural community pharmacists integrating care for people with complex health needs

Nissen, L. M. and Tett, S. E. (2005). Rural community pharmacists integrating care for people with complex health needs. Brisbane: Pharmacy Guild of Australia.

Rural community pharmacists integrating care for people with complex health needs

2005

Conference Publication

Use of non-selective non-steroidal anti-inflammatory drugs (NSAID), COX-2 inhibitors (COX-2) and paracetamol

Barozzi, N. and Tett, S.E. (2005). Use of non-selective non-steroidal anti-inflammatory drugs (NSAID), COX-2 inhibitors (COX-2) and paracetamol. Joint Meeting of ASCEPT and APSA, Melbourne, 4-7 Dec. 2005. Australia: Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists.

Use of non-selective non-steroidal anti-inflammatory drugs (NSAID), COX-2 inhibitors (COX-2) and paracetamol

2005

Journal Article

Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant

Atcheson, Bronwyn A., Taylor, Paul J., Mudge, David W., Johnson, David W., Hawley, Carmel M., Campbell, Scott B., Isbel, Nicole M., Pillans, Peter I. and Tett, Susan E. (2005). Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. British Journal of Clinical Pharmacology, 59 (3), 271-280. doi: 10.1111/j.1365-2125.2004.02235.x

Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant

2005

Conference Publication

Influences on the prescribing of new drugs in rural and urban Queensland: The example of COX-2 inhibitors

Behan, K., Cutts, C. and Tett, S. E. (2005). Influences on the prescribing of new drugs in rural and urban Queensland: The example of COX-2 inhibitors. The Society of Hospital Pharmacists of Australia 27th Federal Conference, Brisbane, 10-13 Nov. 2005. Brisbane: Event Planners Australia.

Influences on the prescribing of new drugs in rural and urban Queensland: The example of COX-2 inhibitors

2005

Journal Article

Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors

Behan, K., Cutts, C. and Tett, S. E. (2005). Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors. Journal of Clinical Pharmacy And Therapeutics, 30 (4), 337-343. doi: 10.1111/j.1365-2710.2005.00648.x

Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors